About: Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $2.58 (-4.80%)
IXHL NASDAQ Incannex Healthcare Inc.
Incannex Healthcare Inc. share price
Atividade de preço de IXHL
Último preço
$ 2,620
Variação (24h)
-0,09 USD (3,32%)
Volume
54.51K
Volume (média 4 sem.)
-
Abertura
$ 2,69
Variação do dia
$ 2,59 - $ 2,75
Fechamento anterior
$ 2,71
Último negócio
29 Oct, 8:05 pm GMT+0
Atrasado
29 Oct, 8:05 pm GMT+0
IXHL price performance
Atrasado
29 Oct, 8:05 pm GMT+0
quote.marketSignals